In a recently published work, Castle et al. developed a breast tissue-specific epigenetic clock using next-generation sequencing data and found that DNAm age acceleration was seen in hormone receptor positive and human epidermal growth factor receptor-2+ (HER2+) breast cancer subtypes but not in triple negative breast cancers (TNBC) [4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.